Pre-market Hot Trades in US Stocks
CRISPR Therap fell 8.36% in pre-market trading. Based on recent important news:
<ol>
<li>
On August 5, CRISPR Therapeutics released its Q2 financial report showing a GAAP earnings per share of -$2.40, missing expectations by $1.01, with revenue of $890,000, below the expected $5.55 million, leading to a 5% drop in stock price.
</li>
<li>
On August 5, analysts gave CRISPR an average rating of &#34;Buy,&#34; with 17 &#34;Strong Buy&#34; or &#34;Buy&#34; ratings, 11 &#34;Hold&#34; ratings, and 1 &#34;Sell&#34; or &#34;Strong Sell&#34; rating, indicating an optimistic market outlook for its future performance.
</li>
<li>
On August 5, the company announced a strategic partnership with Sirius Therapeutics to develop siRNA therapies, planning to conduct Phase II clinical trials of SRSD107 in Europe, showing future growth potential.
</li>
</ol>
Pheton rose 7.00% in pre-market trading. Based on recent important news:
<ol>
<li>
On June 13, XPeng launched the XPeng G7, equipped with a Turing AI chip and L3 level computing power, with pre-sales starting, leading to positive market reactions and a rise in stock price.
</li>
<li>
On May 21, during JP Morgan's Investor Day event, market sentiment was optimistic, with investors favoring call options, anticipating a market rise.
</li>
<li>
On July 9, FORTIOR debuted on its first day, opening at a price higher than its listing price, showing strong market performance.
</li>
</ol>
Top Gainers in Pre-market US Stocks
Adaptimmune Therapeutics rose 53.97% in pre-market trading. Based on recent important news:
<ol>
<li>
On August 4, Adaptimmune Therapeutics announced an acquisition agreement with US WorldMeds to expand its business in oncology and cell therapy. This news drove the stock price up significantly by 53.97%.
</li>
<li>
On August 3, Adaptimmune Therapeutics released its latest financial report, showing revenue growth in the rare disease treatment sector exceeding market expectations, further boosting investor confidence.
</li>
<li>
On August 2, market analysts upgraded their rating for Adaptimmune Therapeutics, believing its innovation capabilities in cell therapy will lead to long-term growth.
</li>
</ol>
Arteris rose 47.62% in pre-market trading. Based on recent key news:
<ol>
<li>
On August 4, Arteris announced a collaboration with AMD to use its FlexGen smart NoC IP to enhance semiconductor design performance and efficiency, significantly boosting the stock price.
</li>
<li>
On August 1, Arteris granted a total of 109,000 restricted stock units to four new employees as incentive bonuses, enhancing market confidence
On August 4th, Arteris's CFO Nicholas B. Hawkins reported the sale of the company's common stock, attracting market attention.
</li>
</ol>
Daxing Optical rose 44.94% in pre-market trading. Based on recent important news:
<ol>
<li>
On August 5th, Alcon announced the acquisition of STAAR Surgical, with a total transaction value of approximately $1.5 billion, enhancing its competitiveness in the ophthalmic device market and driving up Daxing Optical's stock price.
</li>
<li>
On August 5th, the acquisition price of STAAR Surgical was at a 59% premium to its 90-day average stock price, boosting market confidence in the ophthalmic industry.
</li>
<li>
On August 5th, the boards of directors of Alcon and STAAR Surgical unanimously approved the acquisition, further solidifying market expectations
</li>
</ol>

CRSP

PTHL

CRISPR Therap pre-market down 8.36%; Pheton pre-market up 7.00%; Adaptimmune Therap pre-market up 53.97%; Arteris pre-market up 47.62%; Dax Optical pre-market up 44.94%

Pre-market hot trades in US stocks: CRISPR Therap down 8.36% in pre-market; Pheton up 7.00% in pre-market